Biomedical subjects

Louis Aledort

Publications and source records attributed to Louis Aledort.

4 recordsLinked to original sources

PubMed2006

Therapeutic decision-making in inhibitor patients.

A panel of hematologists met to discuss treatment choices in patients with hemophilia A and inhibitors. The group agreed that the management of bleeding episodes is complicated by a variable response to bypassing therapy, uncertainties regarding optimal dosing of NovoSeven, and concerns about the combined use of NovoSeven and FEIBA. Thrombotic risk was rated very low for both agents, and there was consensus that product selection should not be restricted to recombinant products. Cost considerations in therapeutic decision-making were also discussed.

Blood Coagulation Factors↗

PubMed2005

Therapy for haemophilia: recent advances and goals for the future.

In the 20th century, haemophilia evolved from a life-threatening, crippling disease to one for which the prognosis is excellent and many patients lead normal, productive lives. Although dramatic achievements in the treatment of haemophilia have occurred, the current therapies have significant drawbacks. Among these is the relatively high incidence of inhibitor development, the requirement for frequent intravenous infusions to prevent bleeding complications, the lack of effective treatment for established joint disease, and the high cost of treatment. The future goal of haemophilia treatment first and foremost is curing this genetic condition via gene therapy. As this goal is likely many years away, improvements in the current factor products in order to reduce the development of inhibitors and to reduce the frequency of therapy are more immediately achievable goals. Finally, improving the treatment of bleeding complications, particularly in inhibitor patients, and developing novel adjunctive therapies for the management of joint disease are also important goals for the near future. This review will discuss in detail the cu-rrent and future goals of haemophilia therapy.

Clinical Trials as Topic↗

PubMed2004

Prophylactic factor replacement in hemophilia.

Prophylaxis, the regular infusion of coagulation factor concentrates to severe hemophiliacs, has been an evolving therapeutic tool of management for the past three decades. Multiple clinical trials have and continue to be conducted in the field of prophylaxis in an attempt to determine ideal regimens of prophylaxis, its benefits, its risks and costs, and to address still unanswered questions; who to place on prophylaxis, when to start prophylaxis, when (if ever) to stop prophylaxis, etc. We present a detailed review and discussion of the evolution of prophylaxis as a tool in managing patients with hemophilia and we address the major issues and still unanswered questions.

Cost of Illness↗

PubMed2002

Bleeding diathesis in amyloidosis with renal insufficiency associated with Crohn's disease: response to desmopressin.

A 53-yr-old man with a 33-yr history of Crohn's ileocolitis, complicated by arthritis and cologastric fistulization, was diagnosed with GI amyloidosis at the time of proctocolectomy. He had marked proteinuria (4.2 g/24 h) and moderate renal insufficiency (BUN of 35 mg/dl and serum creatinine of 2.5 mg/dl). During the operation, he had severe bleeding that required 11 U of blood. Postoperatively, desmopressin was administered, which resulted in a prompt cessation of bleeding. This case demonstrates the efficacy of desmopressin in reversing the bleeding diathesis in surgical patients with amyloidosis complicated by renal insufficiency.

Amyloidosis↗